GSK terminates collaboration; IDEAYA regains IDE275 and IDE705; cash runway unchanged

IDEAYA Biosciences, Inc.

GSK terminates Collaboration, Option and License Agreement effective 90 days after Dec 4, 2025; programs transferred back to IDEAYA.
IDEAYA to evaluate strategic options for IDE275 (Werner Helicase) and IDE705 (Pol Theta) in 2026.
Company reaffirms cash runway into 2030, unchanged by the termination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.